Kerastem’s core technology centres on the emerging relationship between adipose tissue(fat) and the hair growth cycle.
Androgenetic alopecia (AGA) is the most common form of hair loss in both men and women. It is estimated that in the United Kingdom alone, approximately 15 million men and women suffer with this condition.
Kerastem has initiated market development activities in Europe and Japan. Our US therapeutic pipeline is based upon a foundation of clinical studies and CE marked approved therapy options for patients with Alopecia outside the United States.1
1 Source: 2015 ISHRS: Hair Follicle Stimulation by Stromal Vascular Fraction Enhanced Adipose Transplantation in Baldness, David Perez-Meza, MD, FISHRS
Human adipose tissue (fat) is a unique reservoir of multiple cell types including stem cells and other regenerative cells. A patient’s excess fat is easily collected and provides an abundant source of stem cells and other regenerative cells. The Kerastem technology prepares the patient’s therapy in real time and eliminates the costly process of shipping cells to an off-site facility to grow and expand an adequate dose of cells.